Talk:Sanofi–GSK COVID-19 vaccine
| This is the talk page for discussing improvements to the Sanofi–GSK COVID-19 vaccine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
"VidPrevtyn Beta®" listed at Redirects for discussion
edit
A discussion is taking place to address a potential problem with the redirect VidPrevtyn Beta® and it has been listed for discussion. Readers of this page are welcome to participate at Wikipedia:Redirects for discussion/Log/2023 February 12 § VidPrevtyn Beta® until a consensus is reached. Clovermoss🍀 (talk) 01:09, 12 February 2023 (UTC)
Change in ATC code
editThe WHO has updated the ATC code for COVID-19 vaccines. The marketing authorisations may still need to be updated, but the WHO has already implemented these ATC codes. In the case of this vaccine from Sanofi and GSK, as it relates to a recombinant subunit vaccine, the ATC code to use is J07BN04. How can the ATC code of this page be updated?
WHOCC - ATC/DDD Index Classicwikip (talk) 16:55, 23 April 2023 (UTC)